• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分化型甲状腺癌风险组定义有效性的进一步证据。

Further evidence of the validity of risk group definition in differentiated thyroid carcinoma.

作者信息

Cady B, Rossi R, Silverman M, Wool M

出版信息

Surgery. 1985 Dec;98(6):1171-8.

PMID:4071392
Abstract

Three hundred nine consecutive patients primarily treated at the Lahey Clinic Foundation for differentiated thyroid carcinoma between the years 1961 and 1980 were followed for a median of 13 years and a minimum of 5 years. The recurrence and survival rates of these patients are strikingly different in the low-risk group (men 40 years of age and under and women 50 years and under) compared with the high-risk group (all older patients). Only two patients died and eight others had recurrences but survived in 192 low-risk patients, whereas 18 died and 23 had recurrences in 117 high-risk patients. Thus 20% of patients with recurrence in the low-risk group died but 78% of patients with recurrence in the high-risk group died. Follicular carcinoma and major capsular invasion carries a poor prognosis, but only 22% of low-risk in contrast to 55% of high-risk patients died. The fact that low- and high-risk patients have a separate biology is emphasized by unique sex ratio differences. Low-risk patients have a constant male to female ratio of about 5:1, whereas high-risk patients have progressively increased from 1:3 to a male predominance during the past 5 decades. This study showing unique differences in results by age reemphasizes the concept of basic risk groups in differentiated thyroid cancer. The effect of this basic risk group, as in our previous report, supercedes the effect of pathologic type, extent of local disease, or aspects of therapy and exerts principal control over biologic behavior.

摘要

1961年至1980年间,在拉希诊所基金会接受分化型甲状腺癌主要治疗的309例连续患者,接受了中位时间为13年、最短时间为5年的随访。与高危组(所有年龄较大的患者)相比,这些患者在低危组(40岁及以下男性和50岁及以下女性)中的复发率和生存率有显著差异。192例低危患者中,仅2例死亡,另外8例复发但存活;而117例高危患者中,18例死亡,23例复发。因此,低危组复发患者中有20%死亡,而高危组复发患者中有78%死亡。滤泡癌和包膜严重侵犯预后较差,但低危患者中只有22%死亡,而高危患者中这一比例为55%。独特的性别比例差异强调了低危和高危患者具有不同生物学特性这一事实。低危患者的男女比例恒定在约5:1,而高危患者在过去50年中从1:3逐渐增加到男性占主导。这项按年龄显示结果存在独特差异的研究再次强调了分化型甲状腺癌基本风险组的概念。正如我们之前的报告所述,这种基本风险组的影响超越了病理类型、局部疾病范围或治疗方面的影响,并对生物学行为起主要控制作用。

相似文献

1
Further evidence of the validity of risk group definition in differentiated thyroid carcinoma.分化型甲状腺癌风险组定义有效性的进一步证据。
Surgery. 1985 Dec;98(6):1171-8.
2
[Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].[分化型甲状腺癌的治疗理念——257例患者25年的治疗结果]
Praxis (Bern 1994). 2000 Nov 2;89(44):1779-97.
3
Management and outcome of recurrent well-differentiated thyroid carcinoma.复发性高分化甲状腺癌的管理与预后
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24. doi: 10.1001/archotol.130.7.819.
4
Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis.甲状腺分化型癌中淋巴结转移的影响:配对分析
Head Neck. 1996 Mar-Apr;18(2):127-32. doi: 10.1002/(SICI)1097-0347(199603/04)18:2<127::AID-HED3>3.0.CO;2-3.
5
Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of AGES, MACIS, and risk group scores in Mexican population.分化型甲状腺癌生存与复发的多因素分析。AGES、MACIS及风险组评分在墨西哥人群中有用性的比较评估。
J Exp Clin Cancer Res. 2002 Mar;21(1):79-86.
6
Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.在同一机构接受治疗和随访的高分化甲状腺癌患者的预后因素。
Ann Ital Chir. 2006 Mar-Apr;77(2):107-13.
7
Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis.甲状腺岛状癌患者的长期预后:岛状组织学类型是预后不良的独立预测因素。
Cancer. 2002 Nov 15;95(10):2076-85. doi: 10.1002/cncr.10947.
8
Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.首次放射性碘治疗后复发的甲状腺乳头状癌患者的临床结局
Cancer. 1996 Aug 1;78(3):493-501. doi: 10.1002/(SICI)1097-0142(19960801)78:3<493::AID-CNCR17>3.0.CO;2-U.
9
Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.甲状腺乳头状癌的纯型与滤泡变体:临床特征、预后因素、治疗及生存情况
Cancer. 2003 Mar 1;97(5):1181-5. doi: 10.1002/cncr.11175.
10
Childhood and adolescent thyroid carcinoma.儿童及青少年甲状腺癌
Cancer. 2002 Aug 15;95(4):724-9. doi: 10.1002/cncr.10725.

引用本文的文献

1
Large (>4 cm) Intrathyroidal Encapsulated Well-Differentiated Follicular Cell-Derived Carcinoma Without Vascular Invasion May Have Negligible Risk of Recurrence Even When Treated with Lobectomy Alone.> 无血管侵犯的大 (>4cm) 甲状腺内包膜型分化良好的滤泡细胞衍生癌即使单独行腺叶切除术治疗,复发风险也可忽略不计。
Thyroid. 2023 May;33(5):586-592. doi: 10.1089/thy.2023.0032. Epub 2023 Apr 18.
2
Recurrence Incidence in Differentiated Thyroid Cancers and the Importance of Diagnostic Iodine-131 Scintigraphy in Clinical Follow-up.分化型甲状腺癌的复发率及诊断性碘-131闪烁扫描在临床随访中的重要性。
Mol Imaging Radionucl Ther. 2016 Jun 5;25(2):85-90. doi: 10.4274/mirt.35220.
3
Follicular thyroid carcinoma: differences in clinical relevance between minimally invasive and widely invasive tumors.
滤泡性甲状腺癌:微小浸润性肿瘤与广泛浸润性肿瘤在临床相关性上的差异
World J Surg Oncol. 2015 Jun 4;13:193. doi: 10.1186/s12957-015-0612-8.
4
Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).微创滤泡性甲状腺癌(MIFTC)——欧洲内分泌外科学会(ESES)的共识报告。
Langenbecks Arch Surg. 2014 Feb;399(2):165-84. doi: 10.1007/s00423-013-1140-z.
5
A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.基于监测、流行病学和最终结果(SEER)登记处,对美国癌症联合委员会(AJCC)用于年轻分化型甲状腺癌患者的分期系统进行批判性分析。
Surgery. 2012 Aug;152(2):145-51. doi: 10.1016/j.surg.2012.02.015. Epub 2012 Apr 11.
6
Encapsulated papillary thyroid carcinoma: is it a distinctive clinical entity with low-grade malignancy?包裹性乳头状甲状腺癌:它是一种具有低级别恶性肿瘤特征的独特临床实体吗?
J Endocrinol Invest. 2013 Feb;36(2):78-83. doi: 10.3275/8241. Epub 2012 Jan 31.
7
Pattern of regional metastases and prognostic factors in differentiated thyroid carcinoma.分化型甲状腺癌的区域性转移模式和预后因素。
Acta Otorhinolaryngol Ital. 2009 Dec;29(6):312-6.
8
Follicular thyroid carcinoma invades venous rather than lymphatic vessels.滤泡状甲状腺癌侵犯静脉而非淋巴管。
Diagn Pathol. 2010 Jan 22;5:8. doi: 10.1186/1746-1596-5-8.
9
Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.甲状腺嗜酸细胞瘤:预测恶性的因素及影响预后、治疗决策和结果的因素。
World J Surg. 2010 Apr;34(4):836-43. doi: 10.1007/s00268-009-0357-z.
10
Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors.甲状腺微小乳头状癌患者发生淋巴结转移和复发的危险因素:偶然瘤与非偶然瘤临床相关性的差异。
World J Surg. 2009 Mar;33(3):460-8. doi: 10.1007/s00268-008-9870-8.